Your session is about to expire
← Back to Search
Anti-metabolites
Treatment arm for Arterial Restenosis
N/A
Waitlist Available
Led By Kong Teng Tan, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months post index procedure
Awards & highlights
Study Summary
The purpose of the study is to evaluate the safety and efficacy on the use of drug eluting balloon (DEB) with paclitaxel to treat in-stent restenosis in femoropopliteal arteries.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months post index procedure
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months post index procedure
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Target lesion patency at 6-month follow-up.
Secondary outcome measures
Clinical success up to 12 months post index procedure
Trial Design
1Treatment groups
Active Control
Group I: Treatment armActive Control1 Intervention
SFA angioplasty with In.Pact Admiral drug eluting balloon
Find a Location
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,472 Previous Clinical Trials
484,963 Total Patients Enrolled
Kong Teng Tan, MDPrincipal InvestigatorUniversity Health Network, Toronto
3 Previous Clinical Trials
50 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger